Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“F & L III CORP.
Company Number
5882912
Status
Active
Incorporation Date
20 November 2020 (over 1 year ago)
Company Type
DOMESTIC BUSINESS CORPORATION
Jurisdiction
New York (US)
Registered Address
283 WASHINGTON AVE.
ALBANY
12206
NY
United States
Directors / Officers
CORPORATE SERVICE BUREAU INC, dos process agent
CORPORATE SERVICE BUREAU INC, registered agent
Registry Page
https://appext20.dos.ny.gov/corp_publ...
References to the moon crypto card are actually just reviews of another person’s trademark, reviews were left by username f&lcorpIII apparently to make it appear as if f&l owned the trademark.
“Founded in 2019, Imperative Ventures is a venture capital firm headquartered in Stillwater, Minnesota. The firm seeks to invest in science-based ventures across advanced materials, energy, and industrial biotechnology sectors.
Contact Information
Website
imperative.vc
Year Founded
2019
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital”
https://pitchbook.com/profiles/investor/434242-90
See page 5:
https://www.otcmarkets.com/otcapi/company/financial-report/333822/content
37,000,000 shares to sell when they vest:
https://imperative.vc/team/
https://imperative.vc/team/william-tynan
Bitgift’s countdown clock has maintained the company from bankruptcy and the share price for more restricted share selling at these prices.
Interim CEO Ontario business partner:
Company Information
Company Name
A Touch of Class Fireplaces
Web Site
www.classfireplaces.com
Contact Person
Mrs Rosalie Pisano ( President)
Mr Frank Ottaviani (Mgr General Manager)
https://www.alignable.com/concord-on/a-touch-of-class-fireplaces-inc
45 million restricted shares remain to be sold or cancelled, in 2019 to Will Tynan of imperative Ventures, likely as those shares vest each month Will is selling his vested shares
He has sold 8 million so far it seems:
Share Structure
Market Cap Market Cap
8,887,712
05/26/2022
Authorized Shares
750,000,000
05/26/2022
Outstanding Shares
663,262,060
05/26/2022
Restricted
37,326,725
05/26/2022
Unrestricted
625,935,335
05/26/2022
Held at DTC
30,000,000
05/26/2022
Float
542,450,227
03/29/2022
The CEO could try to buy out those restricted shares to alleviate the selling pressure. 370,000 dollars at .01 a share deletes those shares.
“"We are very excited to move GB-102 into a Phase 2 clinical trial in wet AMD in the fourth quarter of 2022, while expanding our pipeline to address additional vision-threatening retinal and corneal diseases with high unmet patient needs. We plan to use our current cash to advance GB-102, GB-401 and GB-501 to clinical readouts in 2023," said Fred Guerard, PharmD, Chief Executive Officer of Graybug.
GB-102 for wet AMD: Graybug plans to proceed with a Phase 2 clinical trial of an optimized formulation of GB-102 in wet AMD patients following successful demonstration of improved performance in an extensive battery of novel in vitro stress tests. This decision, supported by a significantly more favorable competitive landscape following recent readouts of other long-acting vascular endothelial growth factor (VEGF) inhibitors, is anticipated to result in a six-month data readout available in the third quarter of 2023. "We are confident that our optimized formulation, together with modified patient inclusion criteria, will demonstrate efficacy similar to the current standard of care while also maintaining the unprecedented duration of up to 12 months observed in the ALTISSIMO trial," said Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug.
GB-401 for POAG: In glaucoma, poor patient compliance with eye drops frequently results in suboptimal control of intraocular pressure (IOP), and degeneration of the optic nerve, leading to irreversible vision loss. GB-401 is a potentially first-in-class implant formulation containing a novel prodrug of timolol injected intravitreally with a proprietary applicator, targeting twice-yearly treatment. Initiation of a Phase 1 trial with GB-401 is planned for the first quarter of 2023, with safety and efficacy data expected to be available in the second quarter of 2023.
GB-501 for MPS1 Corneal Clouding: Graybug recently acquired RainBIO, a start-up company based in North Carolina, that developed a first-in-class gene therapy for mucopolysaccharidosis type 1 (MPS1), an inherited lysosomal storage disorder with very high prevalence of corneal clouding despite existing systemic therapies (enzyme replacement or hematopoietic stem cell transplant). GB-501 received Orphan Drug Designation from the FDA and is eligible for a Priority Review Voucher upon approval. Preclinical studies in a dog model of MPS1 demonstrated complete and sustained clearing of the cornea in all dogs, regardless of disease severity, in less than a month following a single intrastromal injection. Two-year animal data support the potential for GB-501 to cure corneal clouding and restore vision in MPS1 patients. All patients required for the Phase 1/2a trial have been identified, IND submission is expected in the second quarter of 2023, and the data readout is expected in the fourth quarter of 2023.
GB-601 for Inherited Retinal Diseases: Inherited retinal disorders such as retinitis pigmentosa, Leber's congenital amaurosis, and Stargardt's disease are the consequence of over 280 genetic mutations. To date, only one drug has been approved to address a single mutation (RPE65), which accounts for a very small fraction of IRDs, leaving the vast majority of patients without therapeutic options. Graybug recently acquired a portfolio of novel cGMP analogs, supported by a well-characterized mode of action and preclinical data in established RP disease models, from Mireca Medicines GmbH, a German preclinical start-up company. Graybug is developing these cGMP analogs as first-in-class, mutation-agnostic long-acting therapeutics to treat a majority of patients with these diseases.
GB-701 for Geographic Atrophy: Geographic atrophy (GA) represents a significant unmet medical need with over five million patients worldwide suffering from this late-stage, age-related macular degeneration for which there is currently no FDA approved treatment. Recent clinical trials have indicated that targeting the complement pathway is suitable for slowing disease progression, but these investigational therapies require up to 12 injections per year. Graybug and Insilico Medicine, a clinical-stage, end-to-end artificial intelligence (AI)-drug discovery company, recently formed a strategic partnership to leverage Insilico's AI-driven small molecule discovery platform with Graybug's unique ocular drug delivery technologies enabling Graybug to develop a sustained-release, locally administered ocular formulation of a potent factor B inhibitor as a potential treatment for this vision-threatening disease.”
You’d want the merger announcement after the fangage purchase is finalized completely so that it does not cause a delay in the merger process
“The acquisition of Fangage is expected to close in the second quarter of 2022, subject to the satisfaction of various closing conditions.
Triller recently entered into a definitive merger agreement with SeaChange International, Inc. (NASDAQ: SEAC). If the transaction is consummated, the combined company will be named TrillerVerz Corp. Its Class A common stock will be listed on Nasdaq.”
July 1 is the “crest” of the year meaning the mid-point so that is the day I’d look for as far as a merger announcement, maybe get in in mid late June to anticipate fangage completion
Attorney letter likely July to coincide with Game of Thrones August 21st release as a passive promotion for the show
About a month and 20 days away here till possibly increase, fill the gap at .0272 before then
After hours trading has been interesting with big trades that don’t seem to effect the bid/ask amounts being offered, maybe options from insiders being turned into common shares, today would be the best day to fill the gap at 1.22 at close.
“Study status:
Recruitment Status : Recruiting
First Posted : February 21, 2021
Last Update Posted : May 20, 2022
See Contacts and Locations
Sponsor:
CNS Pharmaceuticals, Inc.
Collaborator:
Worldwide Clinical Trials
Information provided by (Responsible Party):
CNS Pharmaceuticals, Inc.
Status: Recruiting
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme, Adult
Interventions:
Drug: Berubicin
Drug: Lomustine
Locations:
Mayo Clinic
Phoenix, Arizona, United States
University of Arkansas
Little Rock, Arkansas, United States
Southern California Permanente Medical Group
Los Angeles, California, United States
(and 48 more...)
No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 2024
Estimated Study Completion Date : February 2025
Current Other Pre-specified Outcome Measures
(submitted: May 10, 2022)
Karnofsky Performance Status [ Time Frame: Through study completion an average of 4 years. ]
Evaluate changes in Karnofsky Performance Status (KPS) score between arms
Evaluate changes in patient-reported outcomes [ Time Frame: Through study completion an average of 4 years. ]
Evaluate changes in patient-reported outcomes between arms.
Explore the effect of O[6] methylguanine-DNA methyltransferase (MGMT) methylation [ Time Frame: Through study completion an average of 4 years. ]
explore the effect of O[6] methylguanine-DNA methyltransferase (MGMT) methylation status on response to berubicin and comparison of theses subsets between arms
Impact of re-resection [ Time Frame: Through study completion an average of 4 years. ]
Impact of re-resection on outcomes
Use of bevacizumab [ Time Frame: Through study completion an average of 4 years. ]
Use of bevacizumab between the arms.”
https://clinicaltrials.gov/ct2/show/results/NCT04762069?id=NCT04762069&draw=2&rank=1
“9:21a ET 3/9/2022 - Benzinga
CNS Pharmaceuticals Addresses Recent Share Price Activity
Mentioned: CNSP
Video from John Climaco, CEO of CNS Pharmaceuticals now available on the Company's website
HOUSTON, March 9, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released a video to shareholders reiterating its operational and clinical progress for lead product candidate, Berubicin, and addressing recent share price activity.
"The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market â?? both of which are things out of our control. However, as the CEO, what I do have control over is executing on the day-to-day operations, which I want to reiterate and emphasize, have simply never been stronger. We continue to enroll patients around the world in our potentially pivotal study of Berubicin in the treatment of adult GBM. We have the leading minds in the field around the world working on this trial with us and we have encouraging ongoing dialogue with the FDA to ensure that our potentially pivotal trial continues to represent the state-of-the-art in the field. So, while what we cannot control remains to be a point of frustration, we are committed to continuing to execute our operational excellence to drive recognition in the market of Berubicin and what we believe could be its immense potential for patients â?? the key driver for ultimately generating shareholder value and tremendous hope for GBM patients worldwide," commented John Climaco, CEO of CNS Pharmaceuticals. "We put our heads down every day and continue to charge forward in our mission to change the game in glioblastoma via Berubicin."
Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications. Patient enrollment, randomization and dosing is currently underway, and the Company has a robust lineup of clinical sites located globally which are advancing toward activation and enrollment.
For more information about the ongoing potentially pivotal Berubicin trial, visit clinicaltrials.gov and reference identifier NCT04762069.
To access the video, please visit the Company's website.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”
I expect first results in September/October 2022 given that first results are provided when 50% of all patients are 6 months into the trial, and 6 months after the PR above is September.
Wow what a spike from the vodka ban, 8 bagger for somebody congrats out there
Mining the gap at .34 cents before crypto turns around later in the year
Yearly report due May 25? “Citizens (NYSE:CIA) is likely to report quarterly earnings at $0.34 per share on revenue of $422.63 million.“
4.09 gap filled in chart
Company continues to drill holes and assay the results to expand where the known lithium is in the ground, at some point they have to start taking the lithium out of the ground and selling it to EV battery makers for the stock to run, no guidance yet on when the actual mining of the resources might begin.
Apple and Microsoft needed a way to fund the Matrix without being associated with it due to the negative stigma it would cause (oh look, Apple and Microsoft are building the Matrix), and if you look at the institutional ownership changes this month in VHC the smaller firms are selling and the big firms are buying meaning that the people behind Apple and Microsoft are investing now (along with the CEO) via those back door investments, the key to VHC was never being a patent troll that was the cover story for what will become the primary IT security program for almost every company in the world in the next 2 years, I expect reports on the first companies to implement the matrix to protect their data, and it could not have been built without the lawsuit victories over Apple and Microsoft the past 12 years, it meaning the building of the matrix product and having enough funds to get the company to this point as the front for Microsoft and Apple’s wish to have a 100% secure data protection system created, and if you can understand that then you are seeing the chess game as it is being played. Good luck to all.
And to anyone who reads that some have already filed complaints don’t let that possibility of a complaint being filed prevent you from also filing federal complaints. It is my personal opinion that some custodians are regulated more strictly for certain discriminatory reasons, and the administration promised a more equitable justice system.
For example, how could a regulator not see Tom Nelson’s Twitter statement as a blatant misleading of the investment community::
Tom Nelson stated in a recent tweet that “there are some celebrities in there”, implying “in current partnership with Lisa Nelson’s company that bought FBCD”. He clearly and blatantly implied that Lisa Nelson’s company had already inked deals with celebrities to promote the product. But the literal implication of his Twitter statement is that the celebrities are simply “in the mall, walking around”, with “there” referring to the mall harboring the store. The purposefulness of the deception is proven by the PR which refers to professional athletes frequenting the mall but which further states there is no deal yet with any celebrity, a goal to still be achieved. They claim to have been “approached by celebrities” the same way any store is approached by a celebrity that literally walks towards the store. Literally they are correct, but what is implied in business-speak when you state you have been approached? It means approached in inquiry as in for a partnership. If they can’t prove they were approached in inquiry by a celebrity for a business partnership then that statement in the PR is an obnoxious lie, written without any concern of regulation of their company, and written as if they consider regulators to be non-existent and inapplicable to their company.
SSM monopoly and Krisa provided investors with a deception.
Shareholder value from this company being used to “clean up” expert market companies in return for shares in those cleaned up companies which could do a reverse merger. Otherwise known as an “ATM”, when a CEO uses one company to fund another. Makes sense since this company is a zero why not transfer what’s left of it and start over with a new Twitter pump?
Count the halt-truths in that PR and try not to laugh. Embarrassing and sad that the SEC and Feds let scammers get away with legalized theft. That PR is not even worth an itemized breakdown of the BS within it. The language used by scammers, lie by telling many literal truths that collectively seem to add up to something but individually have zero to actually do with the company’s prospects. The Feds can see that is what is happening ? Unbelievable failure of regulation.
“This prospectus relates to the offer and resale of up to 188,958,629 ordinary shares, no par value (“Ordinary Shares”) of Cenntro Electric Group Limited ACN 619 054 938, an Australian public limited company formerly known as Naked Brand Group Limited (the “Company”), by the Selling Shareholders set forth under “Selling Shareholders” below, consisting of (a) 174,853,546 Ordinary Shares issued in connection with the Distribution (as defined below) of the Acquisition Shares (as defined below) by Cenntro Automotive Group Limited, a Cayman Islands company limited by shares (“CAG”), to its shareholders following the closing of the Combination (as defined below), including 27,751,531 Ordinary Shares distributed to certain shareholders of CAG pursuant to their conversion of the Convertible Notes (as defined below) previously issued to such shareholders into Series A-1 Preferred Shares of CAG in connection with the Combination, (b) 6,925,684 Ordinary Shares issued to two private placement investors in connection with the December 2021 Private Placement (as defined below), (c) 7,151,612 Ordinary Shares issued to an entity associated with Justin Davis-Rice, the former Executive Chairman and former Chief Executive Officer and a current director of the Company, in connection with the previously awarded Incentive Award (as defined below) and (d) 11,839 Ordinary Shares granted to certain former and current non-employee directors of the Company and 15,948 Ordinary Shares underlying options granted to certain former and current non-employee directors of the Company (the “Non-Employee Director Options”), in each case, as compensation for their services on the Company's board. 92,463,001 Ordinary Shares included in this prospectus are subject to a lock-up agreement for 180 days from December 30, 2021.
”
5 day chart consolidation ends at close of trading, couple that with a big update let’s see it fly from there , biotech is a place investors willing look to be unaffected by vax mandate ruling l, even if in foreign countries
As a small company they were actually in a good near term position in regards to the Supreme Court mandate ruling, unaffected, if they could keep their employees under 100 the big names might falter due to staffing issues, opportunity ruined so far
Still looking good
After hours and Tomorrow big chance for news here imo
The male Twitter account said they were doing this for their son, raising the AS to 40 billion for a small apparel company, not sure about the legality of making claims about celebrities etc but Krisa’s tweets regarding this symbol should be investigated by federal authorities, they are MIA for a long time on SSM monopoly, working from home maybe. Who knows, pay check collecting pretending to regulate. An expensive and devastating economic failure to let Krisa get this far without being shut down and look what they did.
Twitter mentioned it that it was bought on December 10
They went through all the trouble of building the website and increased the AS to 40 billion the day the website launches. Why would anyone need that many shares for a small apparel company. Maybe they meant 4 billion?
If this is not a reg D company how can shares be provided to third parties and then dumped without a filing? Maybe there was no shares provided to third parties,
Investors got scared of the AS increase and sold their shares in a panic. Why would an apparel company need 40 billion shares, completely unnecessary why not see if people buy the product first.
It already appears unique, more details about the apparel as differentiated in all aspects
CVSI does something very well in comparison to the competition that is key to investors and customers,
Quality labeling, including truth in brand name and marketing, a crucial legal parameter in the space of GNC and Pharmacy sold products, CVSI is 100% compliant with no issues and the product works as promoted.
Looks like the market is giving this stock a chance
The lower bollinger band is below zero on the one month chart meaning it no longer applies to the SP, making the middle bollinger band the lower bollinger band, at exactly 50% retracement from the recent drop .006, if the company wants it to go higher than that it should announce some initiatives and celebrities etc., the market will give apparel companies a chance in high inflationary economic conditions imo
Unique and professional website, the apparel is interesting and well presented.
2 months and 10 days to new all time lows below .56
Bounce off 50 SMA in a few days maybe near 2.00
Close below lower bollinger band on one month chart for reversal opportunity
When they announce funding for their research I think, maybe on January 23 when the 3 month chart consolidates, but the funding could be dilutive
100% oversold on the one month chart, 100 SMA cross below 200 didn’t happen today, that technical could be what the website launch is waiting for, 5 day chart opportunity is one hour after mid session
Reverse split and more dilution soon